Document:

EX-10.6

 Exhibit 10.6 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 

October 15, 2015 
 Dr. Zheng Wei 

Connect Biopharm LLC 
 4128 Via Candidiz, Suite 145 

San Diego CA 92130 
  

			
	Re:	  	 Notice of Intention to Cease Prosecution of All National Phase

Applications Corresponding to International Application [***]

 Dear Dr. Wei: 

Connect BioPharm LLC (referred to herein as “Company”) and Arena Pharmaceuticals, Inc. (“Licensor”) entered into an
Exclusive License Agreement with an effective date of June 19, 2012 (the “Agreement”), which you signed on behalf of Company. For your convenience please find a copy of the Agreement attached. 

This notice is provided pursuant to Section 5.3 (“Patent Prosecution and Maintenance”) of the Agreement. Section 5.3(a)
specifies that Licensor may at any time cease to provide the Patent Prosecution Services (which are defined in the same Section to refer to the filing, prosecution and maintenance of License Patents and Program Patents), by written notice to
Company. Licensor hereby provides written notice to Company that Licensor does not intend to continue providing these Patent Prosecution Services. If Company elects to assume responsibility for prosecuting and maintaining any of such applications
Company shall have the right to do so at its own cost. 
 For the avoidance of doubt, this letter refers only to the transfer of
responsibility for the prosecution of the above-identified applications. Ownership of the applications remains with Licensor. The obligations of Company under the Agreement, including the consultation provision of 5.3(b) and the notice
provisions of Section 5.3(d), remain in effect. 
 If you have any questions, please contact [***]. 

 

	
	Sincerely,
	
	/s/ Steven W. Spector            
	Steven W. Spector
	Executive Vice President and General CounselEX-10.7

 Exhibit 10.7 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly
disclosed. 
 AMENDMENT #2 TO 

EXCLUSIVE LICENSE AGREEMENT 
 This
Amendment #2 (this “Amendment”) is entered into as of February 23, 2018 (the “Amendment Effective Date”) by and between Arena Pharmaceuticals, Inc. (“Licensor”) and Connect Biopharm LLC (“Company”), and
modifies the Exclusive License Agreement dated June 19, 2012 by and between the parties, as amended (the “Existing Agreement” and together with this Amendment, the “Agreement”). 

The parties hereto agree to amend the Existing Agreement in the following respects: 
  

	1.	 The last sentence of Section 10.1(b) of the Existing Agreement is hereby replaced with the following:

 “At any time prior to or contemporaneous with the filing of an answer to the ICC, the other party may, by written
notice to the party initiating binding arbitration, add any related issues to be resolved.” 
  

	2.	 Section 10.10 of the Existing Agreement is hereby replaced with the following in its entirety:

 “10.10 Notices. Any notice or communication required or permitted under this Agreement shall be in writing
in the English language. Any notice must be delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier confirmed thereafter by any of the foregoing, to the party to be notified at its
address(es) given below, or at any address such party has previously designated by prior written notice to the other. Notice shall be deemed sufficiently given for all purposes upon the earlier of: (a) the date of actual receipt; (b) if
mailed, ten (10) calendar days after the date of postmark; or (c) if delivered by internationally recognized overnight courier, the next business day the courier regularly makes deliveries (taking into consideration the location of the
sending party and the receiving party for international deliveries). 
 If to Company, notices must be addressed to: 

Connect Biopharm LLC 
 12707
High Bluff Drive, Suite 200 
 San Diego CA 92130 

Attention: [***] 
 Telephone:
[***]” 
 If to Licensor, notices must be addressed to: 

Arena Pharmaceuticals, Inc. 

6154 Nancy Ridge Drive 

 San Diego, CA 92121 

Attention: General Counsel 

Telephone: [***] 
  

	3.	 Unless otherwise specifically stated herein, all of the terms and conditions of the Existing Agreement shall
remain in full force and effect. The Agreement constitutes and contains the entire agreement of the parties and supersedes any and all prior negotiations, correspondence, understandings, letters of intent and agreements between the parties
respecting the subject matter hereof. The Agreement may be amended or modified or one or more provisions hereof waived only by a written instrument signed by the authorized representatives of the parties. 

 

	4.	 This Amendment shall become binding when any one or more counterparts hereof, individually or taken together,
shall bear the signatures of both parties. This Amendment may be executed by exchange of PDF copies, and in two or more counterparts, each of which will be deemed an original document, and all of which, together with this writing. will be deemed one
instrument. 

 Whereupon, the parties have caused this Amendment to be executed by their duly authorized agents, as of the Amendment
Effective Date. 
  

			
	ARENA PHARMACEUTICALS, INC.	  	 CONNECT BIOPHARM LLC

  

									
	By:	 	 /s/ Katie Cohen

Name: Katie Cohen
 Title: Associate General Counsel
	 		 	    By:	 	 /s/ Zheng Wei

Name: Zheng Wei
 Title: CEO

			
	Date:  26 February 2018	 		 	    Date:  Feb. 24, 2018EX-10.8

 Exhibit 10.8 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item
601(b)(10). Such excluded 
 information is not material and would likely cause competitive harm to the registrant if publicly
disclosed 
 AMENDMENT #3 TO EXCLUSIVE LICENSE AGREEMENT 

This Amendment #3 (this “Amendment”) is entered into as of November 19, 2020 (the “Amendment Effective Date”), by and between Arena
Pharmaceuticals, Inc. (“Licensor”) and Connect Biopharm LLC (“Company”), and modifies the Exclusive License Agreement, dated June 19, 2012, by and between the parties, as amended (the “Existing Agreement”, and
together with this Amendment, the “Agreement”). 
 The parties hereto agree to amend the Existing Agreement in the following respects: 

 

	1.	 EXHIBIT A—“Licensed Patents as of the Effective Date” is replaced in its entirety with EXHIBIT
A—“Licensed Patents as of the Amendment Effective Date” attached hereto. 

  

	2.	 The following definitions are hereby added to Section 1 (DEFINITIONS) of the Existing Agreement:

 “Marketing Authorization Application” or “MAA” shall mean any new drug application
filed with the applicable Regulatory Authority in a country or other regulatory jurisdiction, which application is required to commercially market or sell a pharmaceutical product in such country or jurisdiction (and any amendments thereto). In the
context of imported drugs, MAA is also known as the Import Drug License (“IDL”) application. 
 “Marketing Authorization
Holder (MAH)” shall mean, with respect to any country, any party or Affiliate thereof who is the holder a Regulatory Approval in such country. 

“MAA Approval” shall mean with respect to a particular country or other regulatory jurisdiction, any approval of an MAA or
other approval, product, or establishment license, registration, or authorization of any Regulatory Authority necessary for the commercial marketing or sale of a pharmaceutical product in such country or other regulatory jurisdiction, excluding, in
each case, any pricing and reimbursement approvals. Any reference to “regulatory approval” in this Agreement shall also be deemed to be an MAA Approval for purposes of this Agreement. 

 

	3.	 Section 2.1 of the Existing Agreement is hereby replaced in its entirety with the following:

 “Section 2.1 License Grant. Subject to the terms of conditions of this Agreement,
Licensor hereby grants to Company, during the term of this Agreement, an exclusive (even as to Licensor, except for internal research purposes), worldwide, royalty-bearing license under the Licensed Technology and the Program Technology to identify,
research, develop, make, have made, use, sell, offer for sale, have sold and import Products (the “License”). Unless expressly prohibited by Applicable Laws in a country, the Company or its Affiliate or sublicensee shall be the Marketing
Authorization Holder (MAH) for a Product in each county in which Company or its Affiliate sells such Product. Company or its Affiliate or its sublicensee will own and solely maintain all MAA Approvals for the Products.” 

  
 1 

	4.	 Unless otherwise specifically stated herein, all of the terms and conditions of the Existing Agreement shall
remain in full force and effect. The Agreement constitutes and contains the entire agreement of the parties and supersedes any and all prior negotiations, correspondence, understandings, letters of intent and agreements between the parties
respecting the subject matter hereof. The Agreement may be amended or modified or one or more provisions hereof waived only by a written instrument signed by the authorized representatives of the parties. 

 

	5.	 This Amendment shall become binding when one or more counterparts hereof, individually or taken together, shall
bear the signatures of both parties. This Amendment may be executed by exchange of PDF copies, and in two or more counterparts, each of which will be deemed an original document and all of which, together with this writing, will be deemed one
instrument. 

 Whereupon, the parties have caused this Amendment to be executed by their duly authorized agents, as of the
Amendment Effective Date. 

 

			
	ARENA PHARMACEUTICALS, INC.

			
	By:	 	 /s/ Vincent Aurentz

			
	Name: Vincent Aurentz
	Title: EVP & CBO
	Date: Nov 20, 2020 | 8:58 AM PST

			
	CONNECT BIOPHARM LLC

			
	By:	 	 /s/ Zheng Wei

			
	Name: Zheng Wei
	Title: CEO
	Date: Nov 20, 2020 | 9:16 AM PST

 
 

  
 2 

 Exhibit A 

Licensed Patents as of the Amendment Effective Date 

[***] 

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]